Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network. This partnership will enable McLaren to deploy MOSAIQ to centralize patient information across radiation oncology, particle therapy and medical oncology into a single user interface, accessible by multi-disciplinary teams across McLaren's multiple locations.

"By developing a long-term agreement with McLaren, Elekta reinforces its leadership in oncology information systems," explained Tomas Puusepp, President and CEO of Elekta. "Our collaboration with McLaren will further strengthen the integration of the entire cancer system to help improve patient care," Puusepp added.

The agreement entered today goes beyond MOSAIQ; it currently includes 15 Elekta linear accelerators, one Leksell Gamma Knife®, seven brachytherapy systems, and Monaco® treatment planning system to further drive improvements in quality and patient safety. The agreement will be booked in Elekta's second half of fiscal year 2013-14 and is valued at more than USD 50 million.

"At McLaren we are committed to delivering the best cancer care in the world. Today, McLaren is one of the largest oncology providers in the State of Michigan and one of the largest in the United States," said Philip A. Incarnati, President and Chief Executive Officer of McLaren Health Care. "We knew we needed a global leader to help us connect our facilities in a way that allows providers to function in a multi-disciplinary fashion. Elekta is that partner," he explained.

McLaren will move to replace its current linear accelerator fleet with Elekta Versa HD™, a single system that delivers high-volume conventional techniques in addition to advanced treatments that require precise targeting. Versa HD is equipped with the Agility™ 160-leaf multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and to maximize the preservation of healthy tissue.

"By choosing Elekta as our partner, we will be able to give our patients access to the most advanced technology for treating cancer," said Justin Klamerus, MD, MMM, Chief Quality Officer and lead for McLaren's community-based cancer programs. "The comprehensive solution provided by Elekta, along with McLaren's slated opening of the Proton Therapy Center in Flint, enables our cancer program to become one of the most advanced radiation oncology providers in the world," highlighted Klamerus. "We have spent 18 months exploring this partnership and we are confident that Elekta will help us transform cancer care for our patients. No mission is greater than this," he added.